In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Aesica Pharmaceuticals S.r.l. Meets New Serialization Requirements with a QAD ERP Upgrade

QAD Enterprise Applications Enterprise Edition facilitated speedy compliance for the Chinese market

SANTA BARBARA, Calif. — July 8, 2014 — QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB), a leading provider of enterprise software and services, announced today that Aesica Pharmaceuticals S.r.l., the Italian division of Aesica Pharmaceuticals Limited, has upgraded to QAD Enterprise Applications Enterprise Edition (QAD EE). The upgrade helped Aesica meet the deadline for a new serialization regulation for the Chinese market. A recently published case study shares the complete details of the implementation and its benefits.

Aesica is a leading pharmaceutical contract development and manufacturing organization (CDMO). The company, operating in a highly regulated industry, had to meet product serialization and tracking regulations to maintain customer safety, while fighting drug counterfeiting, streamlining the recall process and minimizing financial loss.

Aesica Pharmaceuticals was faced with an unexpected challenge when the compliance deadline for a new Chinese serialization regulation was accelerated from twelve-months to three-months. To meet the accelerated deadline, Aesica chose to upgrade to QAD EE, which helped Aesica meet the new serialization regulations.

“QAD has been a great partner to help Aesica meet the unexpectedly accelerated deadline from China,” said Maurizio Beninati, IT Manager Italy, Aesica Pharmaceuticals S.r.l. “We couldn’t have conquered this challenge without their help and expertise.”

Working with QAD, Aesica Pharmaceuticals met the accelerated regulation deadline through leveraging the enhanced serialization capability of QAD EE.

With the successful implementation, Aesica can now:

  • Identify each individual packaging unit down to the smallest sellable unit.
  • Aggregate individual unit serial numbers as packages are bundled, boxed and placed on shipping pallets.
  • Seamlessly track and trace each single pack of medication.
  • Report serial numbers to the required government agencies once products have been produced and imported.

About Aesica

Aesica Pharmaceuticals S.r.l. supplies contract development and contract manufacturing services for finished dose and active pharmaceutical ingredients to the world’s leading pharmaceutical companies and emerging biotechnology organizations. With headquarters in the United Kingdom, it is one of the country’s fastest growing companies. Aesica currently employs approximately 1,300 people at its headquarters in Newcastle upon Tyne and at manufacturing sites in Cramlington, Nottingham and Queenborough in the U.K., as well as Monheim and Zwickau in Germany and Pianezza, Italy. Aesica is a portfolio company of Silverfleet Capital, one of the leading European mid-market private equity firms, which invested in the business in October 2011. For additional information go to .

For media enquiries, please contact Alex Maw, Marketing Director on +44(0)191 2181963 or email 

About QAD – The Effective Enterprise

QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB) is a leading provider of enterprise software and services designed for global manufacturing companies. For more than 30 years, QAD has provided global manufacturing companies with QAD Enterprise Applications, an enterprise resource planning (ERP) system that supports operational requirements, including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. QAD Enterprise Applications is offered in flexible deployment models as on-premise software, in the cloud with QAD Cloud ERP or in a blended environment. With QAD, customers and partners in the automotive, consumer products, food and beverage, high technology, industrial products and life sciences industries can better align daily operations with their strategic goals to meet their vision of becoming more Effective Enterprises.

For more information about QAD, call +1 805-566-6000 or visit

“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.

For additional information, contact:

Patrick McLaughlin
Markit Strategies

Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding projections of revenue, income and loss, capital expenditures, plans and objectives of management regarding the Company’s business, future economic performance or any of the assumptions underlying or relating to any of the foregoing. Forward-looking statements are based on the company’s current expectations. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, “would”, “might”, “plan” and variations of these words and similar expressions are intended to identify these forward looking statements. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to: evolving demand for the company's products and companion products; the ability to sustain license and service demand; fluctuation in revenue and earnings in the software industry; the ability to leverage changes in technology; the ability to sustain customer renewal rates at current levels; third party opinions about the company; the reliability of estimates of transaction and integration costs and benefits; competition in our industry; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. For a more detailed description of the risk factors associated with the company, please refer to the company's latest Annual Report on Form 10-K, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission thereafter. Management does not undertake to update these forward-looking statements except as required by law.